PSA-based screening for prostate cancer: a comparative analysis.
- Author:
Wan-Li CAO
1
;
Fu-Kang SUN
Author Information
1. Department of Urology, Ruijin Hospital Affliated to Shanghai Jiaotong University, Shanghai 200025, China. caowanli@sjtu.edu.cn
- Publication Type:Journal Article
- MeSH:
Humans;
Male;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms;
blood;
diagnosis
- From:
National Journal of Andrology
2013;19(6):559-562
- CountryChina
- Language:Chinese
-
Abstract:
PSA-based screening has always been one of the controversial topics among urological researchers. In spite of its benefit in detecting early prostate cancer, PSA-based screening may not only result in widespread overdiagnosis and overtreatment of an often indolent disease, which is life-threatening in only a minority of patients, but also subject participators to such complications as erectile dysfunction and incontinence. Besides, whether PSA-based screening can reduce prostate cancer specific mortality has received considerable attention. This review offers a comparative analysis of recent studies on PSA-based screening for prostate cancer.
